Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 3
2021 4
2022 0
Text availability
Article attribute
Article type
Publication date

Search Results

7 results
Results by year
Filters applied: . Clear all
Page 1
Systemic short chain fatty acids limit antitumor effect of CTLA-4 blockade in hosts with cancer.
Coutzac C, Jouniaux JM, Paci A, Schmidt J, Mallardo D, Seck A, Asvatourian V, Cassard L, Saulnier P, Lacroix L, Woerther PL, Vozy A, Naigeon M, Nebot-Bral L, Desbois M, Simeone E, Mateus C, Boselli L, Grivel J, Soularue E, Lepage P, Carbonnel F, Ascierto PA, Robert C, Chaput N. Coutzac C, et al. Among authors: naigeon m. Nat Commun. 2020 May 1;11(1):2168. doi: 10.1038/s41467-020-16079-x. Nat Commun. 2020. PMID: 32358520 Free PMC article.
Circulating T-cell Immunosenescence in Patients with Advanced Non-small Cell Lung Cancer Treated with Single-agent PD-1/PD-L1 Inhibitors or Platinum-based Chemotherapy.
Ferrara R, Naigeon M, Auclin E, Duchemann B, Cassard L, Jouniaux JM, Boselli L, Grivel J, Desnoyer A, Mezquita L, Texier M, Caramella C, Hendriks L, Planchard D, Remon J, Sangaletti S, Proto C, Garassino MC, Soria JC, Marabelle A, Voisin AL, Farhane S, Besse B, Chaput N. Ferrara R, et al. Among authors: naigeon m. Clin Cancer Res. 2021 Jan 15;27(2):492-503. doi: 10.1158/1078-0432.CCR-20-1420. Epub 2020 Sep 4. Clin Cancer Res. 2021. PMID: 32887723
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients.
Charrier M, Mezquita L, Lueza B, Dupraz L, Planchard D, Remon J, Caramella C, Cassard L, Boselli L, Reiners KS, Pogge von Strandmann E, Rusakiewicz S, Ferrara R, Duchemann B, Naigeon M, Pignon JP, Besse B, Chaput N. Charrier M, et al. Among authors: naigeon m. Eur J Cancer. 2019 Feb;108:88-96. doi: 10.1016/j.ejca.2018.12.017. Epub 2019 Jan 14. Eur J Cancer. 2019. PMID: 30648633
Predicting immunotherapy outcomes under therapy in patients with advanced NSCLC using dNLR and its early dynamics.
Mezquita L, Preeshagul I, Auclin E, Saravia D, Hendriks L, Rizvi H, Park W, Nadal E, Martin-Romano P, Ruffinelli JC, Ponce S, Audigier-Valette C, Carnio S, Blanc-Durand F, Bironzo P, Tabbò F, Reale ML, Novello S, Hellmann MD, Sawan P, Girshman J, Plodkowski AJ, Zalcman G, Majem M, Charrier M, Naigeon M, Rossoni C, Mariniello A, Paz-Ares L, Dingemans AM, Planchard D, Cozic N, Cassard L, Lopes G, Chaput N, Arbour K, Besse B. Mezquita L, et al. Among authors: naigeon m. Eur J Cancer. 2021 Jul;151:211-220. doi: 10.1016/j.ejca.2021.03.011. Epub 2021 May 19. Eur J Cancer. 2021. PMID: 34022698
Gefitinib plus tremelimumab combination in refractory non-small cell lung cancer patients harbouring EGFR mutations: The GEFTREM phase I trial.
Riudavets M, Naigeon M, Texier M, Dorta M, Barlesi F, Mazieres J, Varga A, Cassard L, Boselli L, Grivel J, NgoCamus M, Lacroix L, Mezquita L, Besse B, Chaput N, Planchard D. Riudavets M, et al. Among authors: naigeon m. Lung Cancer. 2021 Dec 3:S0169-5002(21)00624-3. doi: 10.1016/j.lungcan.2021.11.018. Online ahead of print. Lung Cancer. 2021. PMID: 34953624